CFOappointment News & Analysis
2 articles
Market Mood
Halozyme Therapeutics Projects $1.7–$1.8 Billion Revenue Growth in 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the appointment of David Ramsay as interim CFO on March 12, 2026. The company forecasts revenues between $1.7 billion and $1.8 billion for the year, marking a projected increase of 22% to 30%. Notably, CEO Helen Torley projected royalties from the ENHANZE drug-delivery system to reach $1.1–$1.2 billion. Halozyme also has seven ENHANZE products in development and aims for 40 drugs to be approved or in development by 2028, highlighting its growth trajectory despite the ongoing patent litigation with Merck.
Read More
Telefonica Brasil Appoints Rodrigo Rossi Monari as CFO and IR Officer
Telefonica Brasil has appointed Rodrigo Rossi Monari as its new Chief Financial Officer and Investor Relations Officer. The company stated that the change aims to strengthen its financial leadership and investor engagement strategies. This leadership transition may impact investor sentiment and market performance as the new appointee brings experience in financial management and investor relations. The effect on stock price and market reactions will depend on Monari's strategic initiatives and performance metrics moving forward.
Read More